EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review

Veysel Erol iD, Zeki Güzel iD, İbrahim Ethem Akgün iD, Gökhan Ecer iD

Case Reports in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/crh/5518867 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Hematology, online erschienen am 21.05.2026. Verfasst von Veysel Erol und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Wunderlich syndrome (WS) is a spontaneous, nontraumatic intrarenal or perirenal hemorrhage most commonly related to renal neoplasms, vascular disorders, infection, cyst rupture, or anticoagulation. Clinical severity ranges from self‐limited bleeding to hemorrhagic shock. Case We report a 58‐year‐old woman with triple‐negative myelofibrosis (MF) who was started on hydroxyurea (HU) 500 mg/day and low‐dose acetylsalicylic acid (ASA). On Day 60, she presented with bilateral perirenal and intrarenal hemorrhage confirmed by contrast‐enhanced abdominal computed tomography. ASA was discontinued and bleeding ceased spontaneously. One month later, she represented with recurrent bilateral hemorrhage without ASA exposure and marked neutrophilic leukocytosis. Concomitant purpuric skin lesions, positive antinuclear antibodies (ANA, 1:160), and low C3 levels raised suspicion for a HU‐associated vasculitic process; HU was discontinued. Coagulation parameters at the time of bleeding (INR: 1.2, aPTT: 26.4 s, fibrinogen: 348 mg/dL, and D‐dimer: 0.6 μg/mL) were not consistent with disseminated intravascular coagulation. Despite supportive management, the patient’s condition deteriorated and she died shortly thereafter. The exact cause of death could not be definitively determined.

Conclusion

To our knowledge, this is the first reported case of WS in a patient with MF receiving HU therapy. Clinicians should consider WS in HU‐treated patients presenting with acute flank pain or hematuria and evaluate for potential vasculitic features.

Schlagwörter

Stichwörter der Autor:innen

Wunderlich syndromedrug-induced vasculitishydroxyureamyelofibrosisspontaneous renal hemorrhage

Autor:innen und Institutionen

  • Department of Hematology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
  • Department of Pathology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
  • Department of Radiology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
  • Department of Urology, Konya Karapinar State Hospital, Konya, Turkey.

ORCID-Profile: Veysel Erol, Zeki Güzel, İbrahim Ethem Akgün, Gökhan Ecer

Zitieren

APA

Erol, V., Güzel, Z., Akgün, İ. E., & Ecer, G. (2026). Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/5518867

Vancouver

Erol V, Güzel Z, Akgün İE, Ecer G. Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/5518867

BibTeX
@article{Erol2026,
  author = {Erol, Veysel and Güzel, Zeki and Akgün, İbrahim Ethem and Ecer, Gökhan},
  title = {Hydroxyurea‐Associated Wunderlich Syndrome in Triple‐Negative Myelofibrosis: A Case Report and Literature Review},
  journal = {Case Reports in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crh/5518867}
}
Kostenlos starten →